Non-Hodgkin lymphomas (NHL) are lymphoid tumors that arise by a complex process of
malignant transformation of mature lymphocytes during various stages of differentiation. The …

Non-Hodgkin's lymphoma (NHL) is a heterogeneous class of cancers displaying a diverse
range of biological phenotypes, clinical behaviours and prognoses. Standard treatments for …

Hematological malignancies define a highly heterogeneous set of blood-, bone marrow-,
and organ-associated diseases with highly variable prognoses that constantly relapse upon …

Treatment resistance, whether inherent or acquired, is a major problem reducing the activity
of conventional and newer, molecularly targeted, cancer drugs. A more complex picture of …

Cancer drug resistance is a major problem, with the majority of patients with metastatic
disease ultimately developing multidrug resistance and succumbing to their disease. Our …

Efficacy of chemotherapy in the treatment of distinct malignancies is often hampered by drug
resistance arising in the tumor. Understanding the molecular basis of drug resistance and …

Drugs that target genomically defined vulnerabilities in human tumors have now been
clinically validated as effective cancer therapies. However, the relatively rapid acquisition of …

Abstract Purpose of Review Passive immunotherapy with therapeutic monoclonal antibodies
(mAbs) has revolutionized the treatment of cancer, especially hematological malignancies …

Therapeutic resistance continues to be an indominable foe in our ambition for curative
cancer treatment. Recent insights into the molecular determinants of acquired treatment …

Drug resistance has always been a concern in cancer treatment, often blamed on the
genetic complexity and instability of tumor cells. While studies of cancer cell lines have …